L

Liberum

Investment bank delivering M&A and advisory

Executive Director of Growth & Strategy

Full-TimeUpdated on 10/17/2026
$180k - $220k/yr+ Performance-based incentive + 401(k) match of 4%
Expert
Boise, ID, USA
Hybrid
Business & StrategyBusiness Operations, Corporate Strategy

About the job

Requirements
  • At least 10 years of experience navigating state and local government procurement processes and political dynamics, with an active executive-level network across the Pacific Northwest built by the candidate.
  • A proven record of identifying, qualifying, and winning multimillion-dollar consulting engagements, including serving as the primary architect for Master Contract or RFP wins.
  • Deep knowledge of the business value of enterprise-scale transformations involving Workday, SAP, or Oracle, including business process reengineering and legacy modernization, and the ability to communicate with technical and non-technical executives.
  • A business-building approach to sustainable growth, including well-scoped engagements, suitable clients, and consideration of each deal’s downstream impact on firm capacity, reputation, and trajectory.
  • Experience building and shaping high-performance teams, including decisions about team composition, performance standards, and cultural fit.
  • Demonstrated daily use of AI tools for rapid RFP analysis, stakeholder mapping, competitive intelligence, and market analysis, and experience driving AI adoption within teams.
  • Ability to negotiate complex statements of work and balance agency budget constraints with delivery standards.
  • Experience identifying and forming strategic alliances with Tier-1 system integrators or specialized firms to expand market footprint and win probability.
  • Credibility and relationship skills to represent the firm with agency directors, legislative stakeholders, system integrator leadership, and the firm’s team.
Responsibilities
  • Partner with the firm’s ownership to set and execute its strategic direction and overall vision.
  • Ensure growth initiatives produce meaningful, sustainable business results and strengthen the firm’s long-term trajectory.
  • Participate in firm-wide operational decisions concerning resource allocation, investment priorities, service-line development, and organizational structure.
  • Protect and strengthen the firm’s culture, standards of excellence, and team-first approach as it grows.
  • Build and execute the firm’s regional expansion strategy across Washington, Idaho, Montana, Oregon, and the broader Pacific Northwest.
  • Build long-term relationships with public-sector leaders and establish the firm as a trusted advisor.
  • Use Master Contracts to identify and secure opportunities aligned with agency needs, including compliance modernization, legacy technology replacement, and major enterprise resource planning implementations.
  • Represent the firm at industry events, conferences, and high-level client meetings to build market presence and attract practitioners and agency clients.
  • Identify, vet, and build alliances with system integrators and firms with complementary service lines, determining when to partner and when to compete.
  • Own the firm’s talent strategy, define the profile of an elite consultant, lead recruitment, and make hiring and team-composition decisions.
  • Identify performance gaps and work with Project Directors on team composition and personnel decisions when performance standards are not met.
  • Partner with Project Directors on delivery execution, professional growth, strategic mentoring, and leadership development.
  • Serve as the senior executive escalation point for client relationships, including politically sensitive situations, expectation resets, and relationships requiring senior attention.
  • Partner with Project Directors to provide strategic oversight, pressure-testing, and executive perspective on deliverables.
  • Audit and refine project management, change management, and organizational development products.
  • Use AI to analyze legislative documents, requests for proposals, budget cycles, and regional market data to identify patterns and opportunities that inform growth decisions.
  • Use AI to produce executive-ready regional growth strategies, risk assessments, pipeline presentations, and competitive analyses.
  • Evaluate emerging AI tools and techniques, bring them to the firm, and help keep the firm’s practices current.
  • Develop a rolling 24-month regional market strategy with targets, relationship milestones, and revenue projections.
  • Create tailored strategic capture plans for high-value Master Contracts.
  • Deliver measurable growth in revenue and new engagements attributable to the strategies, relationships, and market positioning developed.
  • Produce AI-synthesized market and budget analysis to guide firm-wide investment, resource allocation, and strategic priorities.
  • Build a curated pipeline of high-quality practitioners available as the firm scales.
  • Formalize strategic alliances that expand market reach and improve win probability.
  • Strengthen the firm’s brand across the Pacific Northwest.
  • Document and maintain a relationship map of agency leaders, chief information officers, program directors, and procurement decision-makers, including relationship status, engagement cadence, and strategic value.
  • Build agency relationships from initial introduction to trusted-advisor status, with progress evidenced by repeat engagements, sole-source opportunities, and proactive outreach from agency leaders.
  • Generate new engagements and contract expansions traceable to relationships built and nurtured.
  • Develop productive system-integrator and partner relationships that result in joint pursuits, teaming agreements, and wins.
Desired Qualifications
  • Experience building a regional practice or business unit from the ground up, from an initial contract to a leading market position.
  • Direct leadership or high-level capture experience in major Pacific Northwest statewide initiatives such as Washington’s OneWA or Oregon’s R2B.
  • Experience designing and implementing AI-driven business-development workflows, legislative budget early-warning systems, AI-powered proposal-generation pipelines, or market-intelligence dashboards.
  • Expert command of Washington State Department of Enterprise Services and regional procurement vehicles, including experience influencing procurement strategy to align with agency outcomes.
  • A track record of managing cooperative-competitive relationships with Tier-1 system integrators and ensuring accountability to client interests.
  • Prior experience as a chief operating officer, vice president, managing director, or in an equivalent role with direct accountability for firm-wide operations, strategy, or financial performance.
  • Experience driving AI adoption across an entire team by building the workflows, standards, and expectations that make AI-enabled delivery routine.

About the company

Panmure Liberum provides investment banking services in the UK and US, focusing on M&A, corporate advisory, and capital raising for quoted companies, institutional investors, and funds. Its work involves advising on mergers and acquisitions, offering strategic financial guidance, and helping clients raise capital through equity or debt, with fees earned from advisory services and transactions. The firm differentiates itself through deep sector knowledge, an entrepreneurial culture, and strong client relationships that give access to a wide investor base. It also pursues growth by expanding in the US and attracting senior talent. The company aims to become a leading market participant in both the UK and US investment banking scenes by delivering tailored financial solutions and executing transactions efficiently for its clients.

Company Size

51-200

Company Stage

N/A

Total Funding

N/A

Headquarters

London, United Kingdom

Founded

2007

Get referred to Liberum

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • September 2026 Picton and July 2026 EnSilica mandates show active deal flow.
  • August 2026 Hays upgrade signals influence in UK small and mid-cap research.
  • Full consolidation after May 2024 merger improves cross-selling and operating leverage.

What critics are saying

  • Listed-company dealmaking remains weak; Panmure Liberum depends on volatile transaction fees.
  • Rivals like Peel Hunt and Numis still compete aggressively for brokers and mandates.
  • If cost plans miss targets, the merger becomes an expensive scale play with no edge.

What makes Liberum unique

  • May 2024 merger created a larger UK independent investment bank with broader coverage.
  • Panmure Liberum combines UK advisory, research, execution, and capital-raising under one platform.
  • US business expanded with three senior hires, adding New York and Florida reach.

Help us improve and share your feedback! Did you find this helpful?

Benefits

  • 401(k) Company Match
  • Health Insurance
  • Dental Insurance
  • Life Insurance
  • Disability Insurance
  • Paid Vacation
  • Paid Holidays
  • Paid Sick Leave
  • Hybrid Work Options

Company News

BioSpace
Mar 27th, 2025
Avacta Therapeutics Announces Presentations At 2025 Aacr Annual Meeting

LONDON and PHILADELPHIA, March 26, 2025 (GLOBE NEWSWIRE) -- Avacta Therapeutics (AIM: AVCT), a life sciences company developing next generation peptide drug conjugates (PDC) targeting powerful anti-tumor payloads directly to the tumor, today announced that the Company will have three presentations at the American Association for Cancer Research (AACR) Annual Meeting from April 25-30, 2025 in Chicago, IL.The poster presentations will feature data from the Company’s proprietary pre|CISION® platform and pipeline of next generation peptide drug conjugates (PDCs), including AVA6000, a PDC consisting of doxorubicin conjugated with a peptide moiety that is specifically cleaved by FAP in the tumor microenvironment via a pharmacokinetics and clinical presentation, and preclinical pharmacology highlights for AVA6103, a PDC comprised of the pre|CISION® peptide linked to exatecan. The third presentation will describe detailed analysis of the target fibroblast activation protein-alpha (FAPα), the protease that forms the basis of the pre|CISION® platform.Details for Avacta’s poster presentations are below and can be found on the AACR website:Abstract Number and Title: #3139: The novel PDC AVA6103 is a FAP-enabled pre|CISION® medicine which targets exatecan, a topoisomerase I inhibitor, to the tumor microenvironment following FAP cleavageSession Category : Experimental and Molecular Therapeutics: Experimental and Molecular Therapeutics Session Title: Therapeutic Approach to Attack the Tumor MicroenvironmentTherapeutic Approach to Attack the Tumor Microenvironment Session Date and Time: Monday, April 28, 2025, 2:00 - 5:00 p.m. CTAbstract Number and Title: #2699: Investigating fibroblast activation protein alpha (FAPα) as a therapeutic target for delivery of pre|CISION® cancer medicines: Expression, spatial localization and functional insightsSession Category : Tumor Biology: Tumor Biology Session Title : Targeting the Tumor Microenvironment: A Brave New World: Targeting the Tumor Microenvironment: A Brave New World Session Date and Time: Monday, April 28, 2025, 2:00 - 5:00 p.m. CTAbstract Number and Title: #CT15: Comparative pharmacokinetics and tumor activation of fibroblast activation protein (FAP)-enabled pre|CISION® peptide drug conjugatesSession Title : First-in-Human Phase I Clinical Trials 2: First-in-Human Phase I Clinical Trials 2 Session Date and Time: Tuesday, April 29, 2025, 9:00 a.m. - 12:00 p.m. CTFor further information from Avacta, please contact:Avacta Group plcMichael Vinegrad, Group CommunicationsDirector www.avacta.com Peel Hunt (Nomad and Broker)James Steel / Chris Goldenwww.peelhunt.com Panmure Liberum (Joint Broker)Emma Earl / Will Goode / Mark Rogers www.panmureliberum.com ICR HealthcareMary-Jane Elliott / Jessica Hodgson / Stephanie [email protected] ContactRenee LeckTHRUST Strategic Communications [email protected] Media ContactCarly ScadutoCarly Scaduto [email protected] Avacta - www.avacta.comAvacta Therapeutics is a clinical-stage life sciences company expanding the reach of highly potent cancer therapies with the pre|CISION® platform

The Independent
Jan 16th, 2024
Panmure Gordon and Liberum agree tie-up to be led by Rich Ricci

Former Barclays boss Bob Diamond's City broker Panmure Gordon has agreed to merge with rival Liberum, with fellow former Barclays executive Rich Ricci hired to head up the new firm.

Bloomberg
Jan 16th, 2024
City of London’s Panmure Gordon, Liberum to Merge in Latest Broker Deal

Panmure Gordon and Liberum have agreed to merge in an all-stock deal, the latest combination of City of London stockbrokers looking to survive a dry spell in dealmaking and fundraising for listed companies.

Insider Media
Sep 29th, 2023
NorthEdge founder partner to become Science in Sport chairman

Dan Wright is set to be appointed as non-executive chairman, subject to the satisfactory completion of due diligence by the company's nominated adviser Liberum Capital.

Financial News London
Sep 18th, 2023
Liberum's Bidhi Bhoma: 'The noise about the US shift in listings is overblown'

When Bidhi Bhoma became CEO of Liberum in December 2020, he took the reins from its founder, Shane Le Prevost, who had steered the company for 13 years.